COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system

COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system

Objective: Although recent evidence suggests no increased risk of severe COVID-19 outcomes associated with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) use, the relationship is less clear among patients with hypertension and diverse racial/ethnic groups. T...

Full description

Bibliographic Details
Main Authors: Jaejin An, Hui Zhou, Rong Wei, Tiffany Q. Luong, Michael K. Gould, Matthew T. Mefford, Teresa N. Harrison, Beth Creekmur, Ming-Sum Lee, John J. Sim, Jeffrey W. Brettler, John P. Martin, Angeline L. Ong-Su, Kristi Reynolds
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:International Journal of Cardiology. Hypertension
Subjects:
Angiotensin converting enzyme inhibitors
Angiotensin receptor blockers
Covid 19
Hypertension
Online Access:http://www.sciencedirect.com/science/article/pii/S2590086221000136

Internet

http://www.sciencedirect.com/science/article/pii/S2590086221000136

Similar Items